Skip to main content
. 2021 May 10;2021:6672987. doi: 10.1155/2021/6672987

Table 1.

Clinical and laboratory data for the RA and CG groups.

Data RA CG p
Sample n (%) 140 40 0.0657
Female 130 (92.8%) 33 (82.5%)
Male 10 (7.2%) 7 (17.5%)

Age in years, mean ± SEM 54.0 (±12.0) 51.5 (±8.5) 0,0943
Race and ethnicity classifications
Indigenous 1 0 ns
Multiracial 49 9 ns
Black or African American 60 22 ns
White 30 9 ns

Disease duration, years, mean ± SEM 10.0 (±7.8)
+ rheumatoid factor (n%) 113 (80.7%)
ESR mm/h, median, (range) 36 (2–125)
Disease classification (n%)
CDAI, mean ± SEM 18.5 (±13.0)
Low disease activity (≤10) 45 (32%)
Moderate and high disease activity (>10) 95 (68%)
DAS28 mean ± SEM 4.5 (±1.5)
Low disease activity (≤3.2) 31 (22.2%)
Moderate and high disease activity (>3.2) 109 (77.8%)

Treatment (n)
None (naïve for treatment) 60
Prednisone only 11
Methotrexate only 12
Leflunomide only 7
More than one treatment 50

Comorbidities (n)
None 109
Diabetes mellitus 9
Obesity 6
Osteoporosis 12
Systemic arterial hypertension 24

CG- control group; SEM- standard error of mean; ESR- erythrocyte sedimentation rate.